Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13789693 | 0.84 | CYP2D6 (0.33) | CYP2D6CYP2C19ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL11914271 | 0.84 | PDK2 (0.35) | PTGES | |
| SCHEMBL14063305 | 0.80 | PDK2 (0.36) | CYP2D6CYP2C19PTGES | |
| SCHEMBL29963982 | 0.80 | PDK2 (0.36) | CYP2D6CYP2C19PTGES | |
| SCHEMBL17863531 | 0.80 | MEN1 (0.40) | CYP2D6CYP2C19CYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL3756278 | 0.80 | HKDC1 (0.33) | CYP2D6CYP2C19ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL29561560 | 0.79 | PDK2 (0.41) | CYP2A6CYP1A2SIRT2MEN1KMT2A | |
| SCHEMBL18553672 | 0.79 | PDK2 (0.41) | CYP2A6CYP1A2SIRT2MEN1KMT2A | |
| SCHEMBL17863532 | 0.78 | MEN1 (0.33) | CYP2D6CYP2C19ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL16683878 | 0.77 | ERN1 (0.35) | CYP2A6ALDH1A1SIRT2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838130-B2 | Aminodibenzofluorene derivative and organic electroluminescence device using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090267491-A1 | AMINODIBENZOFLUORENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090267491-A1 | AMINODIBENZOFLUORENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | L1CAM, DDC, LEF1 | CYP2D6 1341/4885CYP2C19 842/4885CYP2A6 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.